Showing 1181-1190 of 20877 results for "".
- Study Links Vitiligo to Higher Autoimmune and Infection Burden in US Cohorthttps://reachmd.com/news/vitiligo-linked-to-higher-autoimmune-and-infection-burden-in-us-cohort/2486572/New data from a large retrospective study suggested patients with vitiligo experience higher rates of several comorbidities and safety events compared with matched controls. Investigators analyzed Optum Market Clarity EHR dat
- Home-Based Liver Frailty Intervention Shows Feasibility in Pilot Studyhttps://reachmd.com/news/home-based-liver-frailty-intervention-feasibility/2486555/Key Takeaways A home-based liver frailty intervention using remote monitoring with home equipment and app-based support was reported to be feasible. Adherence was partial, but retention remained high and remote frailty assessment was completed during f
- ELEVATE-IPF: New Findings on Deupirfenidonehttps://reachmd.com/news/elevate-ipf-deupirfenidone/2486553/Key Takeaways ELEVATE-IPF randomized patients to deupirfenidone 550 mg, deupirfenidone 825 mg, pirfenidone 801 mg, or placebo. Less FVC decline was reported for combined deupirfenidone versus placebo, and a separate frequentist analysis also reported l
- Navigated TMS Trial Reports PTSD Symptom Improvementhttps://reachmd.com/news/navigated-tms-ptsd-symptom-improve/2486556/Key Takeaways Adjunctive navigated TMS was associated with greater reported PTSD symptom improvement than sham in this randomized trial population. Improvement was reported at one month, and group differences were also reported at three months. </
- CLL Associated With Increased Skin Cancer Risk and Worse Outcomeshttps://reachmd.com/news/cll-associated-with-increased-skin-cancer-risk-and-worse-outcomes/2486544/Key points: Cohort study of more than 13,000 patients with psoriasis evaluated paradoxical eczema risk during biologic therapy Overall incidence was low (~1%), but varied by drug class IL-23 inhibitors were associated with the lowest risk comp
- First Patient Enrolled in IMPROVE-PAH Phase 3 Studyhttps://reachmd.com/news/first-patient-enrolled-in-improve-pah-phase-3-study/2486538/Key takeaways: First patient enrolled in the global, adaptive, two-part Phase 3 IMPROVE-PAH trial of IKT-001 in PAH Part A primary endpoint: change in pulmonary vascular resistance at Week 24; Part B: change in 6-minute walk distance at Week 24
- First Patient Dosed in OYE Therapeutics IV Caffeine 505(b)(2) Bridging Studyhttps://reachmd.com/news/first-patient-dosed-in-oye-therapeutics-iv-caffeine-505b2-bridging-study/2486542/Key points: First patient dosed in a 505(b)(2) bridging study of OYE-101 OYE-101 is an intravenous caffeine formulation designed to accelerate recovery from anesthesia and deep sedation Study will generate human data to support a future 505(b)
- New Data Highlight How Ultrasound Imaging May Improve Safety in High-Risk Filler Injectionshttps://reachmd.com/news/new-data-highlights-how-ultrasound-imaging-may-improve-safety-in-high-risk-filler-injections/2486532/The use of dermal fillers continues to expand across aesthetic practice, accompanied by ongoing concerns regarding vascular adverse events (VAEs), including tissue necrosis and vision loss. In a recent publication in Aesthetic Plastic Surgery, investigators evaluated the role of high-res
- Antenatal MMS in Pakistan and Nigeria: Initiation and Adherencehttps://reachmd.com/news/antenatal-mms-pakistan-nigeria-initiation-adherence/2486523/Key Takeaways: Researchers report very high initiation after receipt of MMS in both Swabi and Bauchi, alongside moderate-to-high adherence patterns that varied by measurement approach and threshold. Across qualitative data, perceived benefits, trust in
- Icotrokinra Shows Sustained Skin Clearance Through 52 Weeks in Psoriasishttps://reachmd.com/news/icotrokinra-shows-sustained-skin-clearance-through-52-weeks-in-psoriasis/2486494/New 52-week data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlight the sustained efficacy and safety of icotro